Alberta-based life science startup PulseMedica Corp. (also known as PulseMedica) has secured 12 million CAD ($8.73 million) in a pre-Series A funding round to accelerate clinical validation of its innovative floater imaging device and other projects in the pipeline.
Co-founded in 2018 by Nir Katchinskiy, Eric Martin, and Thas Yuwaraj Ph.D, PulseMedica focuses on improving the quality of life for millions of patients experiencing visual disorders with unique diagnostics and treatments.
According to the company’s announcement, Saltagen Ventures spearheaded the latest funding round, which also received significant contributions from other investors, including Accelerate Fund III, ThresholdImpact, UCeed Health Fund, ScaleGood Fund, Startup TNT, and the University of Alberta’s Innovation Fund.
The new capital will help PulseMedica propel its innovative floater imaging device to clinical validation, support its ongoing laser safety and feasibility studies, and unveil the first-in-human clinical trial for floater treatment.
Additionally, the funding will enable PulseMedica to expand its technical and medical team in preparation for regulatory approvals and commercialization.
Since 2020, PulseMedica has raised over $16M CAD (about $11.64 million), with $6.5M CAD ($4.73 million) coming from a strategic multinational. The company’s recent funding has fueled substantial progress in its research and development efforts, leading to the development of seven prototypes.
PulseMedica’s Revolutionary Platform
The latest funding shows investors’ confidence and support for the PulseMedica platform, which seeks to transform eye care by providing non-invasive, innovative, and effective imaging and treatment solutions.
The company’s technology has shown the potential to improve ophthalmology and help millions of lives by enhancing the standard of care for eye illnesses. PulseMedica is poised for significant growth and development in the coming days, attracting the interest of lead investors.
According to Dr. Nir Katchinskiy, CEO and Co-founder of PulseMedica, the new financing will enable the company to advance its platform and validate its performance in clinical settings.